Importantly, analysis of the immune cells infiltrating the tumor showed that combination therapy with PTX and IL-34 blocker was superior to PTX monotherapy in reducing the fraction of M-MDSCs and increasing the number of T cells [75]. This evidence concerns the gene IL34 and neoplasm.